Endocrinology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Endocrinology Search

Endocrinology

Endocrinology

Home News Diseases Conferences Special Reports Multimedia

Cardiovascular disease a top killer of Southeast Asian diabetics

Tristan Manalac, an hour ago

Cardiovascular diseases, renal diseases and infections account for majority of the deaths in diabetic Southeast Asians, for which diabetic kidney disease (DKD) is an independent risk factor, according to a recent Singapore study.

OAGB vs RYGB: No difference in weight loss, metabolic effects

Jairia Dela Cruz, 3 days ago

One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.

Metformin protects over 15 years: Time for diabetes prevention indication?

Pearl Toh, 5 days ago

Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.

DIABESITY AND THE ROLE OF DIABETIC-SPECIFIC FORMULA IN IMPROVING DIABETES AND OBESITY OUTCOMES

02 May 2019

At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.

Strategies for the long-term practical management of T2DM

24 Apr 2019

At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.

Fenofibrate linked with reduced CV risk and DR progression, but how?

28 Nov 2018

At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.

Improving glycaemic outcomes and providing cardiovascular protection in patients with T2DM

21 Nov 2018

At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.

Optimizing CV outcomes with evolocumab

Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

Redefining diabetes management: Combining glycaemic control with cardiovascular protection to deliver better patient outcomes

31 May 2018

At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.

New osteoporosis guideline: Who to treat with what

Elvira Manzano, 29 Apr 2019

A new osteoporosis guideline by the Endocrine Society puts a premium on women at high risk of fractures, particularly those who have had a recent fracture after menopause, and outlines the latest pharmacologic options for specific patient groups.

Walking downhill after meals osteoprotective?

Elvira Manzano, 27 Apr 2019

Walking downhill within 1 hour after meals may help reduce bone resorption in postmenopausal women with diabetes, according to new research. Walking uphill does not provide the same osteogenic response.

Novel vaginal ring confers sustained pregnancy prevention up to a year

Pearl Toh, 17 Apr 2019

A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.

Oral semaglutide trumps sitagliptin in reducing HbA1c, weight in uncontrolled T2D

Roshini Claire Anthony, 17 Apr 2019

Individuals with poorly controlled type 2 diabetes (T2D) had greater HbA_1c reductions and weight loss when a 7 or 14 mg/day dose of the GLP-1* receptor agonist semaglutide rather than sitagliptin was added to their background diabetic medications, results of the phase IIIa PIONEER 3** trial showed.

Osilodrostat shows promise for Cushing’s Disease

Pearl Toh, 15 Apr 2019

Treatment with the oral 11β-hydroxylase inhibitor osilodrostat continues to maintain a normalized mean urinary free cortisol (mUFC) in patients with Cushing’s Disease (CD) in a phase III trial presented at ENDO 2019.

Sustained weight loss with testosterone therapy in obese men with hypogonadism

Roshini Claire Anthony, 15 Apr 2019

Long-term testosterone therapy in obese men with hypogonadism led to sustained weight loss and improvements in multiple anthropometric parameters, according to an observational study presented at ENDO 2019.

Male contraceptive pill breaks new ground in the birth control field

Audrey Abella, 11 Apr 2019

The novel androgen 11-beta-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC) – a modified testosterone with androgenic and progestational activity being developed as a male contraceptive – effectively suppressed endogenous gonadotropin and testosterone production in healthy men, consequently preventing pregnancies, according to data presented at ENDO 2019.